Protalix BioTherapeutics (NYSE:PLX) Downgraded to Buy Rating by StockNews.com

Protalix BioTherapeutics (NYSE:PLX) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday.

Separately, HC Wainwright upped their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Trading Down 4.3 %

Shares of PLX opened at $2.25 on Thursday. The firm has a market capitalization of $165.68 million, a P/E ratio of -17.31 and a beta of 0.72. Protalix BioTherapeutics has a 12-month low of $0.82 and a 12-month high of $2.76. The firm has a fifty day moving average price of $2.39 and a 200-day moving average price of $1.74.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several hedge funds have recently made changes to their positions in PLX. Y Intercept Hong Kong Ltd purchased a new position in shares of Protalix BioTherapeutics during the fourth quarter valued at $35,000. XTX Topco Ltd bought a new position in Protalix BioTherapeutics during the 3rd quarter worth about $36,000. Sanctuary Advisors LLC purchased a new position in Protalix BioTherapeutics during the 3rd quarter valued at about $38,000. PFG Investments LLC bought a new stake in shares of Protalix BioTherapeutics in the 4th quarter valued at about $39,000. Finally, Virtu Financial LLC purchased a new stake in shares of Protalix BioTherapeutics in the 3rd quarter worth approximately $44,000. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.